GlobeNewswire: La Jolla Pharmaceutical Company Contains the last 10 of 50 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:06:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/08/06/2074232/0/en/La-Jolla-Pharmaceutical-Company-Announces-Financial-Results-for-the-Three-and-Six-Months-Ended-June-30-2020-and-Highlights-Recent-Corporate-Progress.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress2020-08-06T12:30:00Z<![CDATA[SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2020 and highlighted recent corporate progress.]]>https://www.globenewswire.com/news-release/2020/07/28/2069036/0/en/Larry-Edwards-Appointed-President-and-Chief-Executive-Officer-of-La-Jolla-Pharmaceutical-Company.html?f=22&fvtc=4&fvtv=42445Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company2020-07-28T20:16:00Z<![CDATA[SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer.]]>https://www.globenewswire.com/news-release/2020/07/28/2069027/0/en/La-Jolla-Pharmaceutical-Company-Announces-the-Closing-of-Acquisition-of-Tetraphase-Pharmaceuticals-Inc.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc. 2020-07-28T20:15:00Z<![CDATA[-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- ]]>https://www.globenewswire.com/news-release/2020/06/24/2052639/0/en/La-Jolla-Pharmaceutical-Company-to-Acquire-Tetraphase-Pharmaceuticals-Inc.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.2020-06-24T11:30:00Z<![CDATA[La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights]]>https://www.globenewswire.com/news-release/2020/05/04/2026745/0/en/La-Jolla-Pharmaceutical-Company-Announces-Financial-Results-for-the-Three-Months-Ended-March-31-2020.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 20202020-05-04T12:30:00Z<![CDATA[SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2020.]]>https://www.globenewswire.com/news-release/2020/04/13/2015032/0/en/La-Jolla-Pharmaceutical-Company-to-Provide-GIAPREZA-Angiotensin-II-for-Emergency-Medical-Program-in-Patients-with-Septic-Shock-Due-to-COVID-19-at-CHIREC-Delta-Hospital-Brussels-Bel.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium2020-04-13T12:30:00Z<![CDATA[SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for an emergency medical program in patients with septic shock due to COVID-19 at the Centre Hospitalier Interrégional Edith Cavell (CHIREC) Delta Hospital in Brussels, Belgium. GIAPREZA is being made available for emergency medical use based on a request from Professor Daniel De Backer, M.D., Head, Department of Intensive Care, CHIREC Delta Hospital in Brussels, Belgium. According to Belgian law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA has been recently approved by the European Commission but is not yet commercially available in Europe.]]>https://www.globenewswire.com/news-release/2020/04/07/2012827/0/en/La-Jolla-Pharmaceutical-Company-to-Provide-GIAPREZA-Angiotensin-II-for-Named-Patient-Emergency-Use-in-Patients-with-Septic-Shock-Due-to-COVID-19-at-University-Hospital-M%C3%BCnster-in-G.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany2020-04-07T12:30:00Z<![CDATA[SAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at University Hospital Münster in Germany. GIAPREZA is being made available for named patient emergency use based on a request from Professor Alexander Zarbock, M.D., Chair, Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster. According to German law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA has been recently approved by the European Commission but is not yet commercially available in Europe.]]>https://www.globenewswire.com/news-release/2020/04/06/2012111/0/en/La-Jolla-Pharmaceutical-Company-to-Provide-GIAPREZA-Angiotensin-II-for-Named-Patient-Emergency-Use-in-Patients-with-Septic-Shock-Due-to-COVID-19-at-Royal-Surrey-County-Hospital-Gui.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom2020-04-06T12:30:00Z<![CDATA[SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom. GIAPREZA is being made available for named patient emergency use based on a request from Professor Lui G. Forni, MBBS, Ph.D., at Royal Surrey County Hospital NHS Foundation Trust. According to English law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA has been recently approved by the European Commission but is not yet commercially available in Europe.]]>https://www.globenewswire.com/news-release/2020/04/03/2011457/0/en/La-Jolla-Pharmaceutical-Company-to-Provide-GIAPREZA-Angiotensin-II-for-Named-Patient-Emergency-Use-in-Patients-with-Septic-Shock-Due-to-COVID-19-at-University-Hospital-Frankfurt-in.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany2020-04-03T12:30:00Z<![CDATA[SAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at University Hospital Frankfurt in Germany. GIAPREZA is being made available for compassionate use based on a request from Professor Kai Zacharowski, M.D., Ph.D., ML, FRCA, Director of the Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt. According to German law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA has been recently approved by the European Commission but is not yet commercially available in Europe.]]>https://www.globenewswire.com/news-release/2020/04/02/2010756/0/en/La-Jolla-Pharmaceutical-Company-to-Provide-GIAPREZA-Angiotensin-II-for-Named-Patient-Emergency-Use-in-Patients-with-Septic-Shock-Due-to-COVID-19-at-Guy-s-and-St-Thomas-NHS-Foundati.html?f=22&fvtc=4&fvtv=42445La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom2020-04-02T12:30:00Z<![CDATA[SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom. GIAPREZA is being made available for named patient emergency use based on a request from Marlies Ostermann, M.D., Consultant in Nephrology and Critical Care at Guy’s and St. Thomas’ NHS Foundation Trust, London, England. According to English law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA has been recently approved by the European Commission but is not yet commercially available in Europe.]]>